Krystal Biotech (KRYS) Accumulated Expenses (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Accumulated Expenses of $35.6 million for Q2 2026, up 34.12% year-over-year from $26.5 million in Q2 2025, and up 14.01% on a QoQ basis from $31.2 million in Q1 2026.
Krystal Biotech (KRYS) Accumulated Expenses (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Accumulated Expenses for 11 years, with the latest figure at $35.6 million in Q2 2026.
- Accumulated Expenses for Q2 2026 came in at $35.6 million, up 34.12% year-over-year; the trailing twelve-month figure through Jun 2026 was $35.6 million (up 34.12% YoY), and the FY2025 annual result was $39.8 million, down 32.61% from the prior year.
- Accumulated Expenses rose to $35.6 million in Q2 2026, from $31.2 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $59.0 million in Q4 2024 and troughed at $17.9 million in Q2 2023.
- A 5-year average of $32.6 million and a median of $29.5 million in 2023 frame the typical range for Accumulated Expenses.
- The widest annual swing landed in 2022, when Accumulated Expenses surged 663.94%; it then sank 42.12% in 2023.
- A 5-year view of Accumulated Expenses shows it stood at $23.3 million in 2022, then dropped by 7.7% to $21.5 million in 2023, then soared by 174.23% to $59.0 million in 2024, then tumbled by 32.61% to $39.8 million in 2025, then dropped by 10.53% to $35.6 million in 2026.
- Per Business Quant data, the three most recent Accumulated Expenses figures were $35.6 million in Q2 2026, $31.2 million in Q1 2026, and $39.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.57 Mn |
| Mar 31, 2026 | 31.20 Mn |
| Dec 31, 2025 | 39.75 Mn |
| Sep 30, 2025 | 31.70 Mn |
| Jun 30, 2025 | 26.52 Mn |
| Mar 31, 2025 | 28.05 Mn |
| Dec 31, 2024 | 58.99 Mn |
| Sep 30, 2024 | 53.11 Mn |
| Jun 30, 2024 | 43.33 Mn |
| Mar 31, 2024 | 29.51 Mn |
| Dec 31, 2023 | 21.51 Mn |
| Sep 30, 2023 | 21.74 Mn |
| Jun 30, 2023 | 17.92 Mn |
| Mar 31, 2023 | 29.41 Mn |
| Dec 31, 2022 | 23.31 Mn |
| Sep 30, 2022 | 20.72 Mn |
| Jun 30, 2022 | 23.78 Mn |
| Mar 31, 2022 | 50.82 Mn |
| Dec 31, 2021 | 16.30 Mn |
| Sep 30, 2021 | 30.00 Mn |